cyclopentyladenosine   Click here for help

GtoPdb Ligand ID: 380

Abbreviated name: CPA
Synonyms: N(6)-cyclopentyladenosine | N6-cyclopentyladenosine
PDB Ligand
Compound class: Synthetic organic
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

cyclopentyladenosine is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 4
Topological polar surface area 125.55
Molecular weight 335.16
XLogP 0.3
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OCC1OC(C(C1O)O)n1cnc2c1ncnc2NC1CCCC1
Isomeric SMILES OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2NC1CCCC1
InChI InChI=1S/C15H21N5O4/c21-5-9-11(22)12(23)15(24-9)20-7-18-10-13(16-6-17-14(10)20)19-8-3-1-2-4-8/h6-9,11-12,15,21-23H,1-5H2,(H,16,17,19)/t9-,11-,12-,15-/m1/s1
InChI Key SQMWSBKSHWARHU-SDBHATRESA-N
References
1. Dalpiaz A, Townsend-Nicholson A, Beukers MW, Schofield PR, IJzerman AP. (1998)
Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors.
Biochem Pharmacol, 56 (11): 1437-45. [PMID:9827575]
2. de Ligt RA, Rivkees SA, Lorenzen A, Leurs R, IJzerman AP. (2005)
A "locked-on," constitutively active mutant of the adenosine A1 receptor.
Eur J Pharmacol, 510 (1-2): 1-8. [PMID:15740718]
3. Gao ZG, Mamedova LK, Chen P, Jacobson KA. (2004)
2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors.
Biochem Pharmacol, 68 (10): 1985-93. [PMID:15476669]
4. Heitman LH, Mulder-Krieger T, Spanjersberg RF, von Frijtag Drabbe Künzel JK, Dalpiaz A, IJzerman AP. (2006)
Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine-like agonist.
Br J Pharmacol, 147 (5): 533-41. [PMID:16444290]
5. Jacobson KA, Gao ZG. (2006)
Adenosine receptors as therapeutic targets.
Nat Rev Drug Discov, 5 (3): 247-64. [PMID:16518376]
6. Jockers R, Linder ME, Hohenegger M, Nanoff C, Bertin B, Strosberg AD, Marullo S, Freissmuth M. (1994)
Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor.
J Biol Chem, 269 (51): 32077-84. [PMID:7798201]
7. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ. (1998)
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.
Naunyn Schmiedebergs Arch Pharmacol, 357 (1): 1-9. [PMID:9459566]
8. Liang BT, Urso R, Sambraski E, Jacobson KA. (2010)
.  In  A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics
Edited by Borea PA (Springer) . [ISBN:9789048131440]
9. Linden J, Thai T, Figler H, Jin X, Robeva AS. (1999)
Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells.
Mol Pharmacol, 56 (4): 705-13. [PMID:10496952]
10. Rivkees SA, Barbhaiya H, IJzerman AP. (1999)
Identification of the adenine binding site of the human A1 adenosine receptor.
J Biol Chem, 274 (6): 3617-21. [PMID:9920910]
11. Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG. (1993)
Molecular cloning and characterization of the human A3 adenosine receptor.
Proc Natl Acad Sci USA, 90 (21): 10365-9. [PMID:8234299]